Impact News +++ Semiconductor advances a ′must′ for data centers, says Tokyo Electron boss (Nikkei) +++ TOKYO ELECTRON Aktie +3,50%

IDEAYA Aktie

>IDEAYA Aktienkurs

25.52 EUR -6.6% (TradegateBSX)

Ask: 25.52 EUR / 118 Stück

Bid: 24.53 EUR / 123 Stück

Tagesumsatz: 23 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IDEAYA Aktie über LYNX handeln

Intraday

1 Jahr

>IDEAYA Performance

1 Woche: +1,6%

1 Monat: +8,5%

3 Monate: -9,1%

6 Monate: -16,9%

1 Jahr: +37,0%

laufendes Jahr: -11,3%

>IDEAYA Aktie

Name:

IDEAYA BIOSCIENCE DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45166A1025 / A2PJPB

Symbol/ Ticker:

30J (Frankfurt) / IDYA (NASDAQ)

Kürzel:

FRA:30J, ETR:30J, 30J:GR, NASDAQ:IDYA

Index:

Webseite:

https://www.ideayabio.com..

Profil:

Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2..
>Volltext..

Marktkapitalisierung:

2165.61 Mio. EUR

Unternehmenswert:

1605.11 Mio. EUR

Umsatz:

195.51 Mio. EUR

EBITDA:

-155.24 Mio. EUR

Nettogewinn:

-121.56 Mio. EUR

Gewinn je Aktie:

-1.37 EUR

Schulden:

24.82 Mio. EUR

Liquide Mittel:

136.71 Mio. EUR

Operativer Cashflow:

Bargeldquote:

10.35

Umsatzwachstum:

2913.36%

Gewinnwachstum:

57.29%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IDEAYA

Letzte Datenerhebung:

09.06.26

>IDEAYA Kennzahlen

Aktien/ Unternehmen:

Aktien: 87.86 Mio. St.

Frei handelbar: 94.55%

Leerverk. Aktien: 13.32%

Rückkaufquote: -0.19%

Mitarbeiter: 145

Umsatz/Mitarb.: 1.31 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 78.53%

Bewertung:

KGV: -

KGV lG: -

KUV: 11.2

KBV: 2.7

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 97.96%

Gewinnmarge: -62.17%

Operative Marge: -81.44%

Managementeffizenz:

Gesamtkaprendite: -13.14%

Eigenkaprendite: -14.28%

>IDEAYA Peer Group

Gesundheit, Antikörper- Behandlung, Lungenerkrankungen & -behandlung/ Asthma, Onkologie/ Krebs- Behandlung

>IDEAYA Chart & Kurs - NASDAQ

>IDEAYA News

09.06.26 - 07:09	IDEAYA Biosciences prices $300M public offering of shares and pre-funded warrants at $27/share (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.06.26 - 04:24	IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 5,555,556 shares of common stock and pre-funded warrants to purchase......

08.06.26 - 22:24	Ideaya Biosciences: Aktie fällt nach Ankündigung einer Kapitalerhöhung über 300 Mio. US-Dollar (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

08.06.26 - 22:12	IDEAYA files shelf offering to raise up to $300M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.06.26 - 22:03	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants......

03.06.26 - 17:15	IDEAYA to work with Roche on combo pancreatic cancer treatment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.06.26 - 13:25	Roche und Ideaya testen Wirkstoffkombination gegen Bauchspeicheldrüsenkrebs (Cash)
	Pharma - Roche ist eine Zusammenarbeit mit dem US-Biotechunternehmen Ideaya Biosciences eingegangen....

03.06.26 - 12:03	IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer (PR Newswire)
	IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma IDEAYA will......

01.06.26 - 17:01	IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO (PR Newswire)
	Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs. 3.1 months, HR: 0.42, 58% reduction in risk of disease progression Significantly improved ORR (37.1% vs 5.8%)......

29.05.26 - 12:03	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 28, 2026, the Compensation Committee of IDEAYA's Board......

26.05.26 - 12:03	IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the following events at the 2026 Jefferies Global......

05.05.26 - 14:30	IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
	IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -3.35% and -35.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

05.05.26 - 12:15	IDEAYA Biosciences GAAP EPS of -$1.11 misses by $0.12, revenue of $6.56M beats by $1.52M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.05.26 - 12:01	IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
	Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing......

01.05.26 - 12:03	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 30, 2026, the Compensation Committee of IDEAYA's......

30.04.26 - 12:03	IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program (PR Newswire)
	Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint and will be presented in a late-breaking oral presentation at ASCO 2026 IDEAYA to initiate the RTOR submission process with the first pre-submission in May, with completion of the NDA filing......

21.04.26 - 16:18	IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanom (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3......

13.04.26 - 13:57	IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars (Benzinga)
	IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026. Importance Rank: 1 read more...

13.04.26 - 13:18	IDEAYA Biosciences: Aktie springt nach positiven Studienergebnissen um 27 % (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

13.04.26 - 12:03	IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma (PR Newswire)
	Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30, 0.59; p-value:...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Noli me tangere! - Rühr mich nicht an! - Neues Testament: Evangelium nach Johannes

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram